@FierceMedDev: Edwards looks to a rocky 2014 as Medtronic looms. More | Follow @FierceMedDev
@MarkHFierce: $100M gets CareFusion a minority stake in an Israeli infusion pump maker--they're old friends as well. Story | Follow @MarkHFierce
@MichaelGFierce: New Hologic CEO aims for Dx revenue growth over sale option. Item | Follow @MichaelGFierce
@GalenMoore: Genetic testing: Invitae completes a $40 million series E financing. Release | Follow @GalenMoore
> St. Jude Medical's ($STJ) board of directors authorized a share repurchase of up to $700 million shares of common stock. Item
> Medtronic ($MDT) has launched a global clinical trial of a transcatheter pacemaker system the size of a large vitamin, and the first patient recently received the implant in Austria. Item
> NeuroMetrix ($NURO) said it will work with Omron Medical Devices to distribute its test for diabetic peripheral neuropathy in China. Item
> An FDA advisory panel will consider on Dec. 11 whether to recommend approval for Boston Scientific's ($BSX) Watchman implant, designed to prevent strokes. Story
> Endo Health Solutions' ($ENDP) American Medical Systems arm won the FDA's 510(k) clearance for a new sling system to treat female stress urinary incontinence. Item
> Researchers have developed a mathematical model designed to improve how stents are used to treat coronary heart disease. Item
Biotech News
@FierceBiotech: Alzheimers R&D: The biggest lottery in the industry, with a winning ticket worth an overnight fortune. Story | Follow @FierceBiotech
@JohnCFierce: So what are the 5 worst pharma media ops? Novartis certainly makes the list. Merck of course. Other suggestions? | Follow @JohnCFierce
@DamianFierce: The FDA's still wary of dapagliflozin, AstraZeneca and Bristol-Myers Squibb's once-rejected diabetes drug. More | Follow @DamianFierce
@EmilyMFierce: Nobel winner declares boycott of top science journals. Story via The Guardian | Follow @EmilyMFierce
> AbbVie's second PhIII hep C study confirms cocktail's promise. Item
> Danish officials cite Novo Nordisk for delay of game. Article
> Takeda sways FDA panel with its bowel disease drug despite viral risks. More
> FDA raises safety, efficacy questions for Bristol-Myers' rare-disease drug metreleptin. News
Pharma News
@FiercePharma: Teva braces for a $550M hit from Copaxone generics. Story | Follow @FiercePharma
@EricPFierce: As this story says, Merck was getting heat on Fosamax litigation it is now settling. News | Follow @EricPFierce
@CarlyHFierce: Pfizer loses Supreme Court bid to squash $142M Neurontin verdict. More | Follow @CarlyHFierce
> Drugmakers, beware of tweets that trigger stock moves. Story
> Novo Nordisk in hot water for delaying bad news on Tresiba. News
Pharma Manufacturing News
> Track-and-trace is here ... and now. Editor's corner
> FDA spanks a second Jubilant HollisterStier plant. More
> Alvogen makes a $250M biosimilars investment in Iceland. Story
> Biogen API plant gets nicked by the FDA. Article
> Hospira cuts costs by expanding drug and API production outside of the U.S. News
> Pharma Tech adds capacity as the CMO industry heats up. Report
> Feds close down importer that sold unapproved Botox and cancer drugs. Item
Biotech Research News
> Cellular Dynamics and Jain Foundation partner on stem cell models for muscular dystrophy. More
> GlaxoSmithKline initiates global cancer consortium. Item
> Report: Global malaria R&D needs $8.3B boost over next decade. Story
> Gene discovery could predict responsiveness of antidepressants. Report
> International Stem Cell Corp. finds a new way to reprogram cells. News
> 1 in 100 cancers associated with gene mutation. Article